NASDAQ:NAUT Nautilus Biotechnology (NAUT) Stock Price, News & Analysis → Could Your Accounts Be Frozen? (From Allegiance Gold) (Ad) Free NAUT Stock Alerts $2.69 +0.02 (+0.75%) (As of 05/3/2024 ET) Add Compare Share Share Today's Range$2.64▼$2.8250-Day Range$2.34▼$3.0052-Week Range$2.16▼$4.65Volume65,314 shsAverage Volume69,329 shsMarket Capitalization$336.95 millionP/E RatioN/ADividend YieldN/APrice Target$6.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Nautilus Biotechnology alerts: Email Address Nautilus Biotechnology MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside123.0% Upside$6.00 Price TargetShort InterestHealthy1.95% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.26Based on 8 Articles This WeekInsider TradingAcquiring Shares$108,316 Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($0.68) to ($0.80) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.32 out of 5 starsMedical Sector499th out of 904 stocksAnalytical Instruments Industry16th out of 29 stocks 3.0 Analyst's Opinion Consensus RatingNautilus Biotechnology has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageNautilus Biotechnology has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.95% of the float of Nautilus Biotechnology has been sold short.Short Interest Ratio / Days to CoverNautilus Biotechnology has a short interest ratio ("days to cover") of 14.5, which indicates bearish sentiment.Change versus previous monthShort interest in Nautilus Biotechnology has recently decreased by 7.50%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldNautilus Biotechnology does not currently pay a dividend.Dividend GrowthNautilus Biotechnology does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NAUT. Previous Next 2.4 News and Social Media Coverage News SentimentNautilus Biotechnology has a news sentiment score of 0.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.42 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Nautilus Biotechnology this week, compared to 1 article on an average week.Search Interest3 people have searched for NAUT on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Nautilus Biotechnology insiders have bought more of their company's stock than they have sold. Specifically, they have bought $108,316.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders42.50% of the stock of Nautilus Biotechnology is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions50.71% of the stock of Nautilus Biotechnology is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Nautilus Biotechnology are expected to decrease in the coming year, from ($0.68) to ($0.80) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Nautilus Biotechnology is -4.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Nautilus Biotechnology is -4.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNautilus Biotechnology has a P/B Ratio of 1.35. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Colonial MetalsThe Gold Grab of the CenturyWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.That's why we have released our Free Precious Metals Investment Guide. About Nautilus Biotechnology Stock (NASDAQ:NAUT)Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. It also offers proteome analysis system, a high-resolution optical imaging system for integrated fluidics and liquid handling sub-system. In addition, the company provides sample preparation, flow cells, multi-affinity probe reagents, and instrument buffers system to perform multi-cycle analysis runs. Nautilus Biotechnology, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.Read More NAUT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NAUT Stock News HeadlinesMay 1, 2024 | msn.comNautilus Biotechnology, Inc. (NASDAQ:NAUT) Q1 2024 Earnings Call TranscriptMay 1, 2024 | finance.yahoo.comNautilus Biotechnology Inc (NAUT) Q1 2024 Earnings Call Transcript Highlights: A Detailed ...May 5, 2024 | Allegiance Gold (Ad)Could Your Accounts Be Frozen?The US Dollar Is "Finished" A deteriorating economy, global instability, and a weakened banking system have pushed the U.S. financial system to the brink, imperiling the value of your savings and investments.May 1, 2024 | finance.yahoo.comQ1 2024 Nautilus Biotechnology Inc Earnings CallApril 30, 2024 | investorplace.comNAUT Stock Earnings: Nautilus Biotechnology Beats EPS for Q1 2024April 30, 2024 | finance.yahoo.comNautilus Biotechnology Inc (NAUT) Q1 2024 Earnings: Narrower Loss Than ExpectedApril 30, 2024 | msn.comNautilus Biotechnology GAAP EPS of -$0.15 beats by $0.01April 30, 2024 | globenewswire.comNautilus Biotechnology Reports First Quarter 2024 Financial ResultsMay 5, 2024 | Allegiance Gold (Ad)Could Your Accounts Be Frozen?The US Dollar Is "Finished" A deteriorating economy, global instability, and a weakened banking system have pushed the U.S. financial system to the brink, imperiling the value of your savings and investments.April 28, 2024 | americanbankingnews.comNautilus Biotechnology (NAUT) Scheduled to Post Quarterly Earnings on TuesdayApril 25, 2024 | msn.comJeff Bezos Earns So Much He Could Buy a Rolex Every Second — How Does He Make Money?April 16, 2024 | morningstar.comNautilus Biotechnology Inc Ordinary Shares NAUTApril 11, 2024 | globenewswire.comNautilus Biotechnology to Announce First Quarter 2024 Financial Results on April 30, 2024March 12, 2024 | msn.comStartup Mahakumbh Redefines India's Esports and Gaming IndustryMarch 11, 2024 | finance.yahoo.comThis Nautilus Biotechnology Insider Increased Their Holding In The Last YearMarch 1, 2024 | seekingalpha.comNautilus Biotechnology, Inc. (NAUT) Q4 2023 Earnings Call TranscriptFebruary 29, 2024 | finance.yahoo.comNautilus Biotechnology, Inc. (NASDAQ:NAUT) Q4 2023 Earnings Call TranscriptFebruary 29, 2024 | finance.yahoo.comQ4 2023 Nautilus Biotechnology Inc Earnings CallFebruary 28, 2024 | finance.yahoo.comNautilus Biotechnology Inc (NAUT) Reports Fiscal Year 2023 Financial ResultsFebruary 28, 2024 | globenewswire.comNautilus Biotechnology Reports Fourth Quarter and Fiscal Year 2023 Financial ResultsFebruary 22, 2024 | globenewswire.comNautilus Biotechnology to Participate in the TD Cowen 44ᵗʰ Annual Healthcare ConferenceFebruary 15, 2024 | finance.yahoo.comSkyWater Signs Production Agreement with Nautilus Biotechnology to Fabricate Novel Biomedical DevicesFebruary 7, 2024 | msn.comWill any Seattle startups go public this year? Analysts see better climate for tech IPOsJanuary 24, 2024 | finance.yahoo.comWith 33% ownership, Nautilus Biotechnology, Inc. (NASDAQ:NAUT) insiders have a lot at stakeJanuary 8, 2024 | markets.businessinsider.comNeuroPace Announces Preliminary Unaudited Revenue for Fourth Quarter and Full Year 2023 and Provides Business UpdatesDecember 14, 2023 | morningstar.comNautilus Biotechnology Inc Ordinary SharesNovember 17, 2023 | msn.comStartup tips from Isilon co-founder Sujal Patel on product-market fit, recruiting, hiring, scrappinessSee More Headlines Receive NAUT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nautilus Biotechnology and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/28/2024Today5/05/2024Next Earnings (Estimated)8/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Analytical instruments Sub-IndustryN/A Current SymbolNASDAQ:NAUT CUSIPN/A CIK1808805 Webwww.nautilus.bio Phone206-333-2001FaxN/AEmployees167Year FoundedN/APrice Target and Rating Average Stock Price Target$6.00 High Stock Price Target$6.00 Low Stock Price Target$6.00 Potential Upside/Downside+123.0%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.55) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-63,670,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-24.94% Return on Assets-21.70% Debt Debt-to-Equity RatioN/A Current Ratio20.09 Quick Ratio19.39 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.99 per share Price / Book1.35Miscellaneous Outstanding Shares125,260,000Free Float72,027,000Market Cap$336.95 million OptionableOptionable Beta1.22 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMr. Sujal M. Patel (Age 49)Co-Founder, CEO, President, Secretary & Director Comp: $827.24kDr. Parag Mallick Ph.D. (Age 46)Co-Founder, Chief Scientist & Director Comp: $562.8kMs. Anna Mowry (Age 40)CFO & Treasurer Comp: $519.21kMs. Mary E. Godwin (Age 65)Senior Vice President of Operations Mr. Matthew B. Murphy ESQ. (Age 59)General Counsel Comp: $382.64kMr. Chris BlessingtonVice President of Corporate Marketing & CommunicationsMs. Gwen E. Weld (Age 66)Chief People Officer Comp: $390.97kMr. Nick A. Nelson (Age 40)Chief Business Officer & Senior VP of Business Development Dr. Subra Sankar Ph.D. (Age 64)Senior Vice President of Product Development Comp: $38.47kMore ExecutivesKey CompetitorsTenaya TherapeuticsNASDAQ:TNYAPacific Biosciences of CaliforniaNASDAQ:PACBAkoya BiosciencesNASDAQ:AKYASeerNASDAQ:SEERBioAtlaNASDAQ:BCABView All CompetitorsInsiders & InstitutionsChina Universal Asset Management Co. Ltd.Bought 9,624 shares on 4/29/2024Ownership: 0.019%Sujal M PatelBought 12,044 shares on 3/11/2024Total: $34,204.96 ($2.84/share)Sujal M PatelBought 18,854 shares on 3/7/2024Total: $54,488.06 ($2.89/share)Sujal M PatelBought 7,405 shares on 3/5/2024Total: $19,623.25 ($2.65/share)Perceptive Advisors LLCBought 3,483,060 shares on 2/26/2024Ownership: 10.079%View All Insider TransactionsView All Institutional Transactions NAUT Stock Analysis - Frequently Asked Questions Should I buy or sell Nautilus Biotechnology stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Nautilus Biotechnology in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" NAUT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NAUT, but not buy additional shares or sell existing shares. View NAUT analyst ratings or view top-rated stocks. What is Nautilus Biotechnology's stock price target for 2024? 1 brokerages have issued 1 year price targets for Nautilus Biotechnology's stock. Their NAUT share price targets range from $6.00 to $6.00. On average, they expect the company's share price to reach $6.00 in the next twelve months. This suggests a possible upside of 123.0% from the stock's current price. View analysts price targets for NAUT or view top-rated stocks among Wall Street analysts. How have NAUT shares performed in 2024? Nautilus Biotechnology's stock was trading at $2.99 at the beginning of the year. Since then, NAUT stock has decreased by 10.0% and is now trading at $2.69. View the best growth stocks for 2024 here. When is Nautilus Biotechnology's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 7th 2024. View our NAUT earnings forecast. How were Nautilus Biotechnology's earnings last quarter? Nautilus Biotechnology, Inc. (NASDAQ:NAUT) announced its quarterly earnings results on Wednesday, February, 28th. The company reported ($0.14) EPS for the quarter, beating analysts' consensus estimates of ($0.16) by $0.02. During the same quarter in the previous year, the business posted ($0.11) earnings per share. Who are Nautilus Biotechnology's major shareholders? Nautilus Biotechnology's stock is owned by many different retail and institutional investors. Top institutional investors include China Universal Asset Management Co. Ltd. (0.02%). Insiders that own company stock include Anna Mowry, Gwen E Weld, Life Sciences Maste Perceptive, Matthew B Murphy, Matthew L Posard, Matthew S Mcilwain, Perceptive Advisors Llc, Subramanian Sankar and Sujal M Patel. View institutional ownership trends. How do I buy shares of Nautilus Biotechnology? Shares of NAUT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:NAUT) was last updated on 5/5/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldElon to Transform U.S. Economy? Porter & CompanyAutomatic Income (from home)Awesomely, LLCCould Your Accounts Be Frozen?Allegiance GoldCharles Payne Demystifies OptionsUnstoppable ProsperityThe asset beating inflation by 4xColonial MetalsUrgent Nvidia WarningAltimetryThe A.I. story nobody is telling you (Read ASAP)TradeSmith Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nautilus Biotechnology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
